Aclaris Therapeutics, Inc. (ACRS)
$6.01-$0.15 (-2.44%) Today
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 12 | 320,022 | |
| Option exercise | 14 | 211,710 | |
| Tax withholding / forfeiture | 1 | 12,385 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
34 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Neal Walker - Officer | Option exercise | Common Stock | 9,466 | - | - | |
| Neal Walker - Officer | Tax withholding / forfeiture | Common Stock | 2,721 | $4.07 | $11K | |
| Neal Walker - Officer | Option exercise | Restricted Stock Units | 9,466 | $0.00 | - | |
| Anand Mehra | Open-market purchase | Common Stock | 666,666 | $2.25 | $1.50M | |
| Neal Walker - Officer | Option exercise | Common Stock | 9,467 | - | - | |
| Neal Walker - Officer | Tax withholding / forfeiture | Common Stock | 2,721 | $2.09 | $6K | |
| Neal Walker - Officer | Option exercise | Restricted Stock Units | 9,467 | $0.00 | - | |
| Neal Walker - Officer | Option exercise | Common Stock | 9,467 | - | - | |
| Neal Walker - Officer | Tax withholding / forfeiture | Common Stock | 2,722 | $1.18 | $3K | |
| Neal Walker - Officer | Option exercise | Restricted Stock Units | 9,467 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 34 ACRS filings on record.
Aclaris Therapeutics, Inc. (ACRS) had 7 insider filings in the last 90 days, with the most recent on 2026-08-04. The full record for ACRS runs to 34 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ACRS were filed in the last 90 days. 1 purchase is on record for this company.
No insider sales of ACRS were filed in the last 90 days. 1 sale is on record for this company.
This page tracks ACRS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ACRS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
